Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Pharmacological Research, 2022 The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj +2 more sources
SAR and QSAR in Environmental Research, 2014 Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Haneesh Jasuja, Om Silakari
exaly +5 more sources
Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors. [PDF]
Molecules, 2019 Janus kinase 2 (JAK2) inhibitors represent a promising therapeutic class of anticancer agents against many myeloproliferative disorders. Bioactivity data on pIC50 of 2229 JAK2 inhibitors were employed in the construction of quantitative structure ...
Simeon S, Jongkon N.
europepmc +2 more sources
Frontiers in Medicine, 2023 Aberrant activation of the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is common in systemic lupus erythematosus (SLE), conferring immune-mediated properties in target tissues.
Dionysis Nikolopoulos +4 more
doaj +3 more sources
Frontiers in Microbiology, 2021 Coronavirus disease 2019 (COVID-19) has caused a crisis to global public health since its outbreak at the end of 2019. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of COVID-19, appears to efficiently evade the host immune ...
Rong Wang +7 more
doaj +2 more sources
Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia. [PDF]
Cureus, 2022 Yıldız J, Batgi H.
europepmc +3 more sources
Janus kinase 2 negative polycythemia vera [PDF]
Asian Biomedicine, 2017 Background A Janus kinase 2 (JAK2) mutation polycythemia vera (PV) is a common manifestation of stem cell disorder. However, available data on the clinical and treatment response of JAK2-negative PV patients are limited. Objectives We report the case and
Pravinwan Thungthong +4 more
semanticscholar +2 more sources
miR-101 Promotes Breast Cancer Cell Apoptosis by Targeting Janus Kinase 2
Cellular Physiology and Biochemistry, 2014 Aims: microRNA-101 (miR-101) is down-regulated in several cancers. In this study, we explored the effects of dysregulated miR-101 on breast cancer cells and the underlying mechanisms. Methods: miR-101 level was quantified by real-time RT-PCR.
Lu Wang +10 more
doaj +2 more sources
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm [PDF]
South Asian Journal of Cancer, 2017 Context: Alterations in megakaryocyte morphology are the hallmark of myeloproliferative neoplasms (MPNs). These neoplasm are also associated with Janus kinase 2 (JAK2) V617F mutation in nearly 95% patients with polycythemia vera (PV), 40% patients of ...
Shuchi Ghai, Sharada Rai
doaj +3 more sources
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study [PDF]
Journal of the American Academy of Dermatology, 2023 Pablo A. Jimenez +9 more
exaly +2 more sources